FRESENIUS MEDICAL CARE NORTH AMERICA for FRESENIUS MEDICAL CARE NORTH AMERICA
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
The BETTER Kidney Care Act (not yet introduced) S.3343/H.R. 5534, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act The Administrations CMMI Model for Kidney Disease - ESRD Treatment Choices Model. Proposed rule/Final for Medicare Advantage program requirements for contract years 2021 and 2022. COVID-19 emergency aid packages and CARES Act CMS Telehealth Waivers Centers for Medicare & Medicaid Services (CMS) final Medicare Advantage (MA) and Part D rule ESRD Seamless Care Organizations (ESCO) Models S. 3548-CARES ACT & future COVID-19 relief packages Milcon-VA Appropriations
Foreign entity interest: Fresenius Medical Care AG and Co. KGaA is the sole indirect owner of Fresenius Medical Care Holdings, Inc. (dba Fresenius Medical Care North America) and has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER F BUKI | — |
| STACEY FAHRNER | — |
| LAURA KEMPER | — |
| CAMERON LYNCH | — |
| TALEEN MEKHDJAVAKIAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.